Rhythm Biosciences (ASX:RHY) has secured a strategic partnership with CancerIQ, a US digital oncology platform, to drive the commercial adoption of its geneType cancer risk assessment technology.
The agreement provides Rhythm with immediate access to more than 65 US health systems and 345 clinics, including major networks like Mount Sinai and the University of Pittsburgh Medical Center.
By embedding geneType directly into CancerIQ's existing clinical workflows, Rhythm bypasses the need to build a direct US sales force, significantly reducing capital requirements and execution risk.
The integration allows healthcare providers to order geneType tests through an automated "ordering wizard" that populates patient data seamlessly.
Unlike traditional hereditary testing that focuses on rare mutations, geneType combines common genetic variants with clinical and lifestyle factors to provide a comprehensive baseline risk model.